DiaMedica Therapeutics Inc
NASDAQ:DMAC
DiaMedica Therapeutics Inc
Free Cash Flow
DiaMedica Therapeutics Inc
Free Cash Flow Peer Comparison
Competitive Free Cash Flow Analysis
Latest Figures & CAGR of Competitors
Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
DiaMedica Therapeutics Inc
NASDAQ:DMAC
|
Free Cash Flow
-$20.3m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-15%
|
|
Abbvie Inc
NYSE:ABBV
|
Free Cash Flow
$21.9B
|
CAGR 3-Years
7%
|
CAGR 5-Years
11%
|
CAGR 10-Years
16%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Free Cash Flow
$7.9B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
8%
|
|
Amgen Inc
NASDAQ:AMGN
|
Free Cash Flow
$7.1B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
2%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Free Cash Flow
$3.5B
|
CAGR 3-Years
5%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Free Cash Flow
$3.9B
|
CAGR 3-Years
25%
|
CAGR 5-Years
13%
|
CAGR 10-Years
27%
|
See Also
What is DiaMedica Therapeutics Inc's Free Cash Flow?
Free Cash Flow
-20.3m
USD
Based on the financial report for Mar 31, 2024, DiaMedica Therapeutics Inc's Free Cash Flow amounts to -20.3m USD.
What is DiaMedica Therapeutics Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
-15%
Over the last year, the Free Cash Flow growth was -59%. The average annual Free Cash Flow growth rates for DiaMedica Therapeutics Inc have been -24% over the past three years , -21% over the past five years , and -15% over the past ten years .